Andel and Novo Bring Wegovy to a Direct-to-Employer Pharmacy Channel

Andel and Novo have announced a direct-to-employer distribution collaboration for Wegovy, creating another route for employers to help fund obesity medications outside conventional pharmacy benefit designs. The arrangement was announced on October 28, 2026 and covers Wegovy injection, Wegovy HD and the once-daily Wegovy pill.

This is a manufacturer-to-employer-marketplace partnership, not a disclosed contract between Novo and a named employer. Andel's announcement includes a statement from Novo's senior vice president for market access and public affairs, supporting the existence of the collaboration. It does not identify employer clients that have elected the new offering.

How the employer model works

Andel describes a cooperative medication marketplace connecting employers and drug manufacturers. Under the newly announced collaboration:

• Employers set a contribution toward an eligible employee's prescribed Wegovy treatment, rather than committing to an undisclosed universal benefit amount.
• Manufacturer-direct pricing is offered through Andel's pharmacy platform, alongside existing employee health benefits.
• Andel coordinates prescription verification and delivery through its application.
• Employees can continue using their existing clinicians; Andel says its program operates outside traditional pharmacy insurance processing.

Andel's employer-facing materials describe a pay-per-fill model, under which employers pay when participating members fill prescriptions. The October announcement does not publish the full commercial terms governing the Novo collaboration or establish whether every employer on Andel's platform has immediate access to each formulation.

This structure is distinct from a conventional pharmacy benefit manager (PBM) rebate arrangement. It also differs from an employer negotiating an exclusive direct purchase agreement with the manufacturer. The public evidence supports a manufacturer-to-platform arrangement offered to employers, not a signed agreement with any particular employer.

What is known—and what remains undisclosed

Measure	Publicly documented status
Manufacturer	Novo, the maker of Wegovy
Employer purchasing platform	Andel
Announcement date	October 28, 2026
Medication category	Obesity treatment / GLP-1 pharmacy
Products named	Wegovy injection, Wegovy HD and Wegovy pill
Geography	United States; employer-by-employer availability not specified
Purchasing structure	Employer-defined contribution, manufacturer-direct pricing, pay-per-fill marketplace
Named employer adopters	Not disclosed
Incremental employees or covered lives	Not disclosed
Andel–Novo negotiated price or employer fees	Not disclosed
Contract term, launch utilization or employer savings	Not disclosed

Novo Nordisk separately confirmed that the Wegovy pill became available nationally in January 2026 and Wegovy HD received FDA approval in March 2026. Those earlier product milestones are not new October launches. The October development is the new employer purchasing channel.

Savings: a purchasing proposition, not a measured outcome

Andel markets the model as reducing insurance friction and giving employers control over drug contributions. The partners have not provided a deal-specific rate card, PBM-versus-direct comparison, utilization figures, employer administrative costs, or a measured net-spend outcome.

An employer's chosen contribution could reduce an employee's out-of-pocket payment, but that is not equivalent to demonstrated savings for the employer. Any claim about total cost of care would also need to account for program fees, eligibility, treatment persistence and the comparator pharmacy benefit.

The DirectContract Deal Tracker therefore records no realized savings percentage, employee count or named employer conversion for this collaboration.

Why this matters

Employer direct contracting is extending beyond hospitals, primary care and surgery into manufacturer-linked specialty pharmacy purchasing. Obesity medications are a particularly visible test because employers must balance employee access with recurring pharmacy costs and eligibility design.

Andel's arrangement offers a defined-contribution alternative to a traditional formulary carve-out. The next meaningful disclosures will be actual employer adoption, the all-in price employers and members pay, administrative charges, and whether claims or utilization data show a durable difference from conventional pharmacy benefits.

For other models of direct healthcare purchasing, see the Deal Tracker and the transparent pricing model.

Primary sources

• Andel, October 28, 2026 — collaboration with Novo to bring Wegovy directly to employers
• Andel — employer purchasing model
• Novo Nordisk, January 5, 2026 — Wegovy pill availability
• Novo Nordisk, March 19, 2026 — Wegovy HD FDA approval